Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. platelys

PLATELYS

PlateLys: The innovative human platelet lysate especially designed to maximize the effectiveness of cell-based therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 PLATELYS project word cloud

Explore the words cloud of the PLATELYS project. It provides you a very rough idea of what is the project "PLATELYS" about.

start    turnover    cellular    endanger    transmission    founders    reactions    portfolio    2016    collect    point    million    cells    supplements    platelet    indispensable    unprecedented    standardized    icelandic    substitute    maximal    oriented    8    hpl    mad    native    ups    amenable    worth    shift    environment    fetuses    hormones    winning    optimization    52    thanks    calf    market    grade    engineered    patented    mimic    inactivated    date    ongoing    profile    solution    sacrificed    immune    staff    2017    created    leads    14    powder    platome    patient    acute    isolated    cagr    flexibility    2021    source    combining    platelys    period    lethal    therapeutic    cell    safety    disease    borne    patients    300    2025    highest    animal    implanted    stem    viral    lysates    lysate    area    species    remarkable    inhumanely    sera    certified    culture    tissue    diseases    billion    previously    approved    cultured    fast    formulation    seek    commercialization    award    quality    therapies    expand    complete    leverage    serum    starting    human    cross    vitro    fulfilling    cow    fda    nonviable    operators    negatives    clinical    gmp    substantial   

Project "PLATELYS" data sheet

The following table provides information about the project.

Coordinator		 PLATOME LIFTAEKNI EHF 

Organization address
address: ALFASKEIDI 27
city: HAFNARFJORDUR
postcode: 220
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Iceland [IS]
 Project website https://platome.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PLATOME LIFTAEKNI EHF IS (HAFNARFJORDUR) coordinator 50˙000.00

Map

 Project objective

Cellular therapies making use of stem cells, engineered immune cells or engineered tissue represent an unprecedented and fast-growing therapeutic area. To date, 14 cell therapies have been approved by the FDA. However, the cells being implanted to the patient need to be cultured in vitro at some point under highly specific and controlled conditions. One of these conditions –indispensable to culture any type of isolated cell in vitro– involves using animal-derived serum as a source of hormones and growth factors to mimic cells' native environment. It is estimated 1.5 million calf fetuses are inhumanely sacrificed to collect serum. This leads (among other negatives) to endanger patient's safety, because of cross-species immune reactions (which may be lethal) and the transmission of animal borne diseases (e.g. the mad cow disease). PlateLys is PLATOME´s solution to develop and produce a remarkable human-based serum substitute fulfilling all the requirements to culture cells. PLATOME is an award-winning Icelandic start-up created in 2016 to leverage the substantial know-how on human platelet lysates (hPL) production from its founders. PlateLys is the only hPL combining: a viral-inactivated hPL ensuring the highest safety profile for patients and operators; a clinical-grade lysate with standardized quality control and GMP certified amenable for research and clinical set-ups; a powder formulation providing maximal flexibility, especially on applications that were nonviable previously. The market of sera supplements will be worth €1.14 billion by 2025 (CAGR of 8%, period 2017-2025) with a large shift to hPL use ongoing. Through the PlateLys project we seek to complete the optimization and scale-up production, starting commercialization activities in Europe by 2021. By 2025, we will have generated €5.52 million in turnover and increase our staff by 300%. PlateLys will allow us to expand our portfolio of cell-oriented products, thanks to our patented production technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PLATELYS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PLATELYS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More